MassHealth Manager Addresses High-Cost Therapy Budgets

Clinical pharmacy manager Katelyn B. Meyer highlights the fiscal challenges of emerging specialty treatments.

Updated on Oct. 28, 2026 in Healthcare

Isometric editorial illustration featuring stacked cubes and a brass-colored geometric medical icon, representing pharmaceutical budget management for high-cost therapies. — MassHealth clinical pharmacy manager Katelyn B. Meyer evaluated the budgetary hurdles of funding life-saving, high-cost specialty gene therapies at AMCP Nexus 2026. AI Illustration. Upload story photo >

Live Poll

Should insurance providers be required to cover expensive, off-label specialty medical treatments?

Katelyn B. Meyer, a clinical pharmacy manager at MassHealth, discussed the financial impact and access issues surrounding high-cost specialty therapies at the AMCP Nexus 2026 meeting. The discussion focused on how payers manage budgets for treatments that often exceed $500,000 per patient.

Why it matters

While specialty therapies address significant unmet needs, their high costs and the rapid growth of gene therapies create substantial budgetary pressures for healthcare payers. Managing these expenses requires careful coordination to ensure patients receive access to essential treatments.

Many emerging specialty therapies cost over $500,000 per patient, while rare disease gene therapies can reach $3 million per patient. Some new formulations have reduced oncology infusion times significantly, from 4 hours down to 10 minutes.

The players

Katelyn B. Meyer

She serves as the clinical pharmacy manager at MassHealth and provides expertise on managed care for specialty therapies.

MassHealth

It is the public health insurance program for low-income residents in Massachusetts.

AMCP Nexus 2026

This is a professional conference focused on managed care pharmacy practices and industry trends.

The details

Payers frequently utilize single-case agreements to secure patient access at out-of-state centers when local options are unavailable. To monitor efficacy and barriers, insurers are increasingly implementing follow-up plans that track patient outcomes for 1 to 2 years.

October 28, 2026: Katelyn B. Meyer participated as a panelist.

Market Landscape

The discussion at AMCP Nexus 2026 highlights the ongoing tension between medical innovation and the financial realities of payer systems, a challenge that persists alongside the Inflation Reduction Act's Medicare drug-price negotiation provisions. This reflects a broader industry push to balance life-saving access with fiscal sustainability.

These budgetary challenges influence how and when patients access cutting-edge treatments, potentially leading to delays or the need for out-of-state travel. Consumers may see insurers implement stricter oversight and long-term monitoring as a requirement for coverage of expensive therapies.

The takeaway

Payers are shifting toward more robust, long-term monitoring models to ensure the value of high-cost therapies is realized for patients. Stakeholders must continue to coordinate closely to navigate the intersection of rapid medical advancement and sustainable healthcare funding.